Experimental cancer drug DS-9606a tested in early trial, but stopped early

NCT ID NCT05394675

Terminated Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we have limited information on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DS-9606a (an experimental antibody-drug conjugate given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for certain advanced cancers that express Claudin-6.
What could go wrong: This is a very early Phase 1 trial that was terminated, so results are limited. The drug may not be effective or safe enough to continue development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer germ cell tumor metastatic malignant neoplasm neoplasm Neoplasm Metastasis Neoplasms, Germ Cell and Embryonal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER GERM CELL TUMOR METASTATIC CANCER

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Florida Cancer Specialists & Research Institute, LLC

Fort Myers, Florida, 33916, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
SCRI at HealthONE

Denver, Colorado, 80216, United States
Sarah Cannon Research Institute UK

London, W1G 6AD, United Kingdom
The Royal Marsden NHS Trust

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.